Editor-in-Chief Marty Makary, MD, MPH, of Johns Hopkins in Baltimore, and
Joshua M. Sharfstein, MD, vice dean for public health practice and community engagement at Johns Hopkins Bloomberg School of Public Health
, discuss whether the pandemic has permanently changed the way the public expects the FDA to operate and the lessons learned with emergency use authorizations (EUAs) for COVID-19.
Following is a transcript of their remarks; note that errors are possible.
Makary: Hi, I'm Marty Makary and I'm here with Dr. Josh Sharfstein. He is vice dean of the Johns Hopkins Bloomberg School of Public Health and former deputy commissioner of the FDA and former Maryland health secretary. Josh, great to have you with us.